surmount-1 trial tirzepatide weight loss results reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 Tirzepatide proves to be more

GLP-1 medications can greatly reduce how much you eat some studies estimate by as much as 40% which makes prioritizing nutrient-dense, protein-rich foods that much more important

P.ValeW

According to the Medicines and Healthcare products Regulatory Agency (MHRA) approved Summary of Product Characteristics (SmPC), dizziness is listed as a common adverse reaction (affecting up to 1 in 10 people)

Saito-Takatsuji H, Yoshitomi Y, Ishigaki Y, Yamamoto S, Numata N, Sakai Y

Additionally, people with severe obesity and heavy drinkers were the ones most likely to cut back

Your thyroid and endocrine provider should communicate during tirzepatide treatment